Press releases

22
Aug 2018
12:00 E.S.T.

Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO

Read more
2
Aug 2018
20:30 E.S.T.

Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer

Read more
1
Aug 2018
20:30 E.S.T.

Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018

Read more
27
Jun 2018
20:30 E.S.T.

Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018

Read more
12
Jun 2018
20:30 E.S.T.

Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports

Read more
8
Jun 2018
21:45 E.S.T.

Shareholders’ General Meeting of June 26, 2018

Read more
4
Jun 2018
20:30 E.S.T.

FDA Grants Cellectis IND Approval for UCART22 in B-ALL

Read more
22
May 2018
23:15 E.S.T.

Approval of UCART123 Amendment in AML to Accelerate Clinical Development

Read more
22
May 2018
20:00 E.S.T.

Calyxt Announces Successful Closing of $60.9 Million Public Offering

Read more
21
May 2018
12:30 E.S.T.

Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US